MRI to check Response to chemotherapy in Breast cancer patients
- Conditions
- Malignant neoplasm of breast of unspecified site,
- Registration Number
- CTRI/2021/06/034325
- Lead Sponsor
- Dr Smiti Sripathi Research Award For Breast Imaging Endowment Fund
- Brief Summary
This is an observational prospective study of patients undergoing Neoadjuvant chemotherapy for treatment of Early/Locally advanced breast cancer at Kasturba Hospital, Manipal. Patients will be selected based on above mentioned inclusion and exclusion criteria. Two MRIs shall be planned - before initiation of chemotherapy and after three cycles. The difference in ADC values in Diffusion weighted sequences and Contrast-enhancement in post-contrast sequences and their relation to complete pathological response to the chemotherapy will be analyzed. The study shall help conclude that MRI scans help predict the complete pathological response to Neoadjuvant chemotherapy via changes in ADC values and post-contrast images.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Female
- Target Recruitment
- 40
- Patients diagnosed with Early breast cancer being treated with Neoadjuvant chemotherapy.
- Patients diagnosed with Locally advanced breast cancer, being treated with Neoadjuvant chemotherapy.
- Baseline and mid-cycle MRI (taken after 3 cycles of chemotherapy) to be taken.
Patients with metastatic carcinoma of breast.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method MRI study (DCE/DWI) of breast, taken Mid-cycle of Neoadjuvant chemotherapy, in Breast cancer patients, effectively helps predict complete pathological response after completion of NAC in Breast cancer patients. One and half year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Kasturba Hospital
🇮🇳Udupi, KARNATAKA, India
Kasturba Hospital🇮🇳Udupi, KARNATAKA, IndiaDr Aantriksha GuptaPrincipal investigator9137177205gupta.arunkumar@learner.manipal.edu